SCHEMBL6425913

SCHEMBL6425913

O=C(Nc1ccc(NC(=O)c2ccc(F)cc2F)c2c1C(=O)c1ccccc1C2=O)c1ccc(F)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
NTRK1 P04629 1/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
AVPR2 P30518 1/20 0.49
GPR27 Q9NS67 1/20 0.49
MEN1 O00255 1/20 0.49
MMP14 P50281 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.48
HDAC1 Q13547 2/20 0.48
PTPRC P08575 2/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
TAS1R2 Q8TE23 1/20 0.48
CTSL P07711 1/20 0.48
PTPN1 P18031 1/20 0.48
CTSS P25774 1/20 0.48
PTPN13 Q12923 1/20 0.48
P2RY4 P51582 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420464 0.86 MEN1 (0.51) MAPTMEN1MMP14KMT2APTPRC
SCHEMBL6421177 0.85 PTPRC (0.59) MAPTNPC1RAB9AMEN1MMP14
SCHEMBL6422899 0.82 MEN1 (0.50) MAPTMEN1MMP14KMT2APTPRC
SCHEMBL6422471 0.80 MEN1 (0.65) MAPTNPC1RAB9AMEN1MMP14
SCHEMBL6421461 0.79 MEN1 (0.60) MAPTNPC1RAB9AMEN1MMP14
SCHEMBL23242582 0.76 SNCA (0.60) MAPTNPC1RAB9AHDAC1TAS1R3
SCHEMBL29800964 0.76 SNCA (0.60) MAPTNPC1RAB9AHDAC1TAS1R3
SCHEMBL30599567 0.76 MAPT (0.71) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL21870353 0.75 HTT (0.56) MAPTNTRK1NPC1RAB9AAVPR2
SCHEMBL6418987 0.75 TP53 (0.57) MAPTNPC1RAB9AGPR27MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives HUANG HSU-SHAN (TW) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives NFE2L2, NR2F2, TFAM MAPT 4766/4885NTRK1 1918/4885NPC1 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.